Liposome nanoparticles have been in existence for nearly two decades. Doxil (doxorubicin liposomal), developed by Sequus Pharmaceuticals Inc., gained FDA approval in 1995. But liposomes have limited use because it's hard to target them to specific tissue and there are very few drugs that can be loaded into and released from liposomes. Read More
Mutations in the genes for BRCA1 and BRCA2 were the first mutations identified that could predict an increased risk of cancer for their carriers. Some of them remain the strongest predictors of such increased risk – carriers of certain mutations have a 75 percent lifetime risk of developing breast or ovarian cancer. Read More
